drugset / Trial / NCT04989140
Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
Phase 4
Unknown
60 enrolled
Peking Union Medical College Hospital
Beijing Chao Yang Hospital · collabBeijing Hospital · collabBeijing Jishuitan Hospital · collabFirst Hospital of China Medical University · collabPeking University Third Hospital · collabSecond Hospital of Shanxi Medical University · collabThe First Affiliated Hospital of Anhui Medical University · collabThe First Affiliated Hospital of Dalian Medical University · collabThe First Affiliated Hospital of Zhengzhou University · collabThe Second Affiliated Hospital of Harbin Medical University · collabTianjin Medical University Cancer Institute and Hospital · collabTianjin Medical University General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of ixazomib, oral dexamethasone and in patients with relapsed multiple myeloma who have received lenalidomide.
Timeline
- Start
- 2021-07-26
- Primary completion
- 2024-07-26
- Completion
- 2024-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Ixazomib | Unknown | 4 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 25 mg | Oral |